# H11-DRUGDELIVERY: Formulation & Delivery Science Agent

## Abstract
H11-DRUGDELIVERY is dedicated to overcoming biological barriers through advanced formulation science. It evaluates excipients, designs nanoparticle/liposome vehicles, and optimizes controlled-release kinetics. The agent ensures that active pharmaceutical ingredients (APIs) achieve optimal oral bioavailability, transdermal penetration, or targeted intracellular delivery.

## Core Capabilities
- **Nanoparticle & Liposome Design:** Computes lipid ratios, zeta potentials, and encapsulation efficiencies for liposomal formulations.
- **Controlled Release Kinetics:** Models zero-order, first-order, and Higuchi release profiles for polymeric matrices.
- **Oral Bioavailability Optimization:** Leverages the Biopharmaceutics Classification System (BCS) to recommend solubilization or permeation enhancement strategies.
- **Transdermal Modeling:** Applies Fick's laws of diffusion to predict flux across the stratum corneum.

## System Architecture
1. `FormulationMatrix`: Evaluates API physicochemical properties against a database of FDA-approved excipients.
2. `ReleaseKineticsSimulator`: Integrates ODEs to model API diffusion from structural matrices (e.g., PLGA, HPMC).
3. `BiobarrierAnalyzer`: Computes permeability coefficients for gastrointestinal and transdermal barriers.

## Interfaces
- **Input:** JSON structural properties of the API (LogP, pKa, melting point, solubility) and the desired administration route.
- **Output:** Formulation recipe (excipient ratios), predicted release profile (T50, T90), and administration strategy.

## Failure Modes & Recovery
- **Incompatible Excipients:** If a drug-excipient interaction is flagged (e.g., amine drug with reducing sugar), the agent automatically substitutes with an inert alternative (e.g., mannitol).
- **Physical Instability:** If predicted zeta potential is near zero (leading to aggregation), the agent iteratively adds steric or electrostatic stabilizers until colloidal stability is achieved.
